In a report released today, Jason Bednar from Piper Sandler maintained a Buy rating on Merit Medical Systems (MMSI – Research Report), with a price target of $95.00. The company’s shares closed yesterday at $78.37.
According to TipRanks, Bednar is an analyst with an average return of -4.9% and a 40.76% success rate. Bednar covers the Healthcare sector, focusing on stocks such as Align Tech, Cooper Co, and DENTSPLY SIRONA.
Currently, the analyst consensus on Merit Medical Systems is a Strong Buy with an average price target of $89.17, which is a 13.78% upside from current levels. In a report released on January 8, Needham also reiterated a Buy rating on the stock with a $81.00 price target.
See today’s best-performing stocks on TipRanks >>
MMSI market cap is currently $4.53B and has a P/E ratio of 45.54.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Merit Medical Systems (MMSI) Company Description:
Merit Medical Systems, Inc. engages in the manufacture and market of proprietary disposable medical devices. It operates through Cardiovascular and Endoscopy segments. The Cardiovascular segment consists of peripheral intervention, cardiac intervention, interventional oncology and spine, and cardiovascular and critical care product groups. The Endoscopy segment integrates advanced non-vascular stent technology with balloon dilators, inflation devices, guide wires, procedure kits, and other devices that are used by gastroenterologists, endoscopists, pulmonologists, and thoracic and general surgeons. The company was founded by Fred P. Lampropoulos, Darla Gill, Kent W. Stanger and William Padilla in July 1987 and is headquartered in South Jordan, UT.
Read More on MMSI:
- Merit Medical Announces Projected Preliminary Unaudited Revenue for the Year Ended December 31, 2023 and Plans to Announce Fourth Quarter and Year End 2023 Results and Issue Fiscal Year 2024 Guidance on February 28, 2024
- Merit Medical report FY23 preliminary revenue $1.255B-$1.259B, consensus $1.25B
- Merit Medical upgraded to Buy from Hold at Canaccord
- Merit Medical announces process for CEO succession planning
- Merit Medical Announces Process for Chief Executive Officer Succession Planning
